Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities
Ornaghi S, Hsieh LS, Bordey A, Vergani P, Paidas MJ, van den Pol AN. Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities. Journal Of Neuroscience 2017, 37: 6877-6893. PMID: 28630251, PMCID: PMC5518418, DOI: 10.1523/jneurosci.0970-17.2017.Peer-Reviewed Original ResearchConceptsAnti-CMV drugsBrain defectsNeurological outcomeCMV replicationMouse brainAvailable anti-CMV drugsHuman fetal brain cellsLong-term neurological outcomeTreatment of cytomegalovirusAdverse neurological outcomesUninfected control miceCommon infectious causeLong-term motorSecond trimester human fetusesUninfected control animalsFetal brain cellsHuman fetal astrocytesJuvenile male miceWeeks of lifeAdverse side effectsEfficacious therapeutic effectsDetectable adverse effectsNewborn mouse brainLevels of virusCMV infection